Damian covers the global drug industry and contributes to STAT’s industry-leading events. You can reach Damian on Signal at damiangarde.67. Johnson & Johnson won U.S. approval to sell the ...

Older adults with severe depression have better outcomes when the antipsychotic aripiprazole (Abilify) is added to their existing antidepressant prescription versus a switch to bupropion, a new study ...

NEW ORLEANS — For older patients with resistant depression who fail to respond to antidepressant treatment, the addition of the atypical antipsychotic aripiprazole (Abilify) is superior to switching ...

For older adults with clinical depression that has not responded to standard treatments, adding the drug aripiprazole (brand name Abilify) to an antidepressant they’re already taking is more effective ...

Dealing with mental health conditions like depression can be challenging. Some people struggle to find the right treatment or combination of treatments for their condition. In major depression ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be used ...

Hoping for some relief, people with treatment-resistant depression (i.e., difficult-to-treat depression) have often tried a variety of interventions. For instance, some have tried contemplative ...

Johnson & Johnson won U.S. approval to sell the antipsychotic drug Caplyta as a treatment for depression, the company said Thursday, a major step in the drugmaker’s efforts to make the medicine a ...